 "Alkem Labs subscribed 35%, Dr Lal PathLabs 65% on Day One")
The Rs 1,300-crore initial public offering (IPO) of Alkem Laboratories was subscribed 35 per cent, while that of Dr Lal PathLabs received 65 per cent subscription on Tuesday. Alkem raised Rs 395 crore, while Dr Lal PathLabs raised Rs 190 crore from anchor investors, including mutual funds and other marquee institutional investors.
Both the companies allotted shares at the top end of the price band; Alkem fixed the priced band for its IPO at Rs 1,020-1,050 a share, while Dr Lal priced it at Rs 540-550 a share. The two IPOs, which opened for subscription on Tuesday, will close on Thursday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app